Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R McKay

Showing results (761-770 of 932) with videos related to

Pageof 94
Sort By:
Cancer|November 6, 2015
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumMarina D Kaymakcalan, Wanling Xie, Laurence Albiges, et al.
JCO Precision Oncology|September 11, 2020
Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate CancerG Celine Han, Justin Hwang, Stephanie A M Wankowicz, et al.
Urology|January 28, 2015
Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patientsJesse D Sammon, Rana R McKay, Simon P Kim, et al.
Clinical Genitourinary Cancer|April 9, 2025
Osteoporosis Amongst Testicular Cancer Survivors: Long Term Follow-Up of the Veterans Affairs Health SystemNuphat Yodkhunnatham, Paul Riviere, Kshitij Pandit, et al.
The Lancet. Oncology|June 11, 2022
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)Neeraj Agarwal, Bradley McGregor, Benjamin L Maughan, et al.
Urologic Oncology|December 3, 2014
The burden of skeletal-related events in patients with prostate cancer and bone metastasisFlorian Roghmann, Carina Antczak, Rana R McKay, et al.
Cancers|May 25, 2024
Characterization of <i>FOLH1</i> Expression in Renal Cell CarcinomaEric Ovruchesky, Elizabeth Pan, Melis Guer, et al.
JAMA Network Open|March 20, 2024
Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer OutcomesRana R McKay, Tyler J Nelson, Meghana S Pagadala, et al.
JCO Global Oncology|February 29, 2020
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large CohortsDominick Bossé, Wanling Xie, Xun Lin, et al.
Molecular Cancer Therapeutics|February 13, 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)Elizabeth Pan, Wanling Xie, Archana Ajmera, et al.
Pageof 94

Showing results (761-770 of 932) with videos related to

Sort By:
Pageof 94
Cancer|November 6, 2015
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumMarina D Kaymakcalan, Wanling Xie, Laurence Albiges, et al.
JCO Precision Oncology|September 11, 2020
Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate CancerG Celine Han, Justin Hwang, Stephanie A M Wankowicz, et al.
Urology|January 28, 2015
Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patientsJesse D Sammon, Rana R McKay, Simon P Kim, et al.
Clinical Genitourinary Cancer|April 9, 2025
Osteoporosis Amongst Testicular Cancer Survivors: Long Term Follow-Up of the Veterans Affairs Health SystemNuphat Yodkhunnatham, Paul Riviere, Kshitij Pandit, et al.
The Lancet. Oncology|June 11, 2022
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)Neeraj Agarwal, Bradley McGregor, Benjamin L Maughan, et al.
Urologic Oncology|December 3, 2014
The burden of skeletal-related events in patients with prostate cancer and bone metastasisFlorian Roghmann, Carina Antczak, Rana R McKay, et al.
Cancers|May 25, 2024
Characterization of <i>FOLH1</i> Expression in Renal Cell CarcinomaEric Ovruchesky, Elizabeth Pan, Melis Guer, et al.
JAMA Network Open|March 20, 2024
Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer OutcomesRana R McKay, Tyler J Nelson, Meghana S Pagadala, et al.
JCO Global Oncology|February 29, 2020
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large CohortsDominick Bossé, Wanling Xie, Xun Lin, et al.
Molecular Cancer Therapeutics|February 13, 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)Elizabeth Pan, Wanling Xie, Archana Ajmera, et al.
Pageof 94